Isovaleric Acidemia (IVA) Treatment Market Report 2026

Isovaleric Acidemia (IVA) Treatment Market Overview

• Isovaleric Acidemia (IVA) Treatment market size has reached to $0.63 billion in 2025 • Expected to grow to $0.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Rising Prevalence Of Metabolic Disorders Fueling The Growth Of The Market Due To Increasing Demand For Metabolic Disease Management • Market Trend: Cryo EM–Guided Small Molecule Stabilizers Drive Next Generation Therapeutics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Isovaleric Acidemia (IVA) Treatment Market?

Isovaleric acidemia (IVA) treatment refers to the medical management of a rare inherited metabolic disorder caused by a deficiency of the enzyme isovaleryl-CoA dehydrogenase, leading to a buildup of isovaleric acid in the body. Treatment focuses on reducing the accumulation of toxic substances and preventing metabolic crises. The main types of isovaleric acidemia (IVA) treatment include classical isovaleric acidemia, moderate isovaleric acidemia, and non-classical isovaleric acidemia. Classical isovaleric acidemia is a severe, inherited metabolic disorder caused by a deficiency of the enzyme isovaleryl-CoA dehydrogenase, which is essential for breaking down the amino acid leucine. Treatments involved for isovaleric acidemia (IVA) treatment are dietary management, enzyme replacement therapy, gene therapy, and pharmacological treatment. The various routes of administration include oral and injectable and are used by several end-users, such as hospitals, clinics, and homecare settings.

What Is The Isovaleric Acidemia (IVA) Treatment Market Growth Forecast?

The isovaleric acidemia (iva) treatment market size is expected to see strong growth in the next few years. It will grow to $0.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in rare disease therapeutics, expansion of genetic counseling services, growing focus on preventive metabolic care, increasing clinical trials for gene therapy, rising investment in orphan drug development. Major trends in the forecast period include increasing adoption of early genetic screening and diagnosis, growing use of carnitine and glycine supplementation, rising focus on personalized dietary management plans, expansion of home-based long-term iva care, increasing research into gene therapy approaches.

Global Isovaleric Acidemia (IVA) Treatment Market Segmentation

1) By Type: Classical Isovaleric Acidemia, Non-classical Isovaleric Acidemia, Moderate Isovaleric Acidemia 2) By Treatment: Dietary Management, Enzyme Replacement Therapy, Gene Therapy, Pharmacological Treatment 3) By Route of Administration: Oral, Injectable 4) By End-user: Hospitals, Clinics, Homecare Settings Subsegments: 1) By Classical Isovaleric Acidemia: Dietary Management, Carnitine Supplementation, Glycine Supplementation, Emergency Management, Gene Therapy (Investigational) 2) By Non-classical Isovaleric Acidemia: Observation and Preventive Care, Mild Dietary Modifications, Occasional Supplementation, Genetic Counseling and Monitoring 3) By Moderate Isovaleric Acidemia: Protein-restricted Diet, Intermittent Carnitine/Glycine Therapy, Periodic Monitoring and Supportive Care, Acute Episode Management

What Are The Drivers Of The Isovaleric Acidemia (IVA) Treatment Market?

The increasing prevalence of metabolic disorders is expected to propel the growth of the isovaleric acidemia (IVA) treatment market going forward. Metabolic disorders are conditions that disrupt normal metabolic processes, affecting how the body converts food into energy. Common types of metabolic disorders include diabetes mellitus, hypothyroidism, hyperthyroidism, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), isovaleric acidemia (IVA), Gaucher disease, Fabry disease, Wilson’s disease, and various lysosomal storage disorders. The prevalence of metabolic disorders is due to lifestyle-related factors such as poor diet and physical inactivity, which contribute to conditions like obesity and insulin resistance. Isovaleric acidemia treatment helps manage metabolic disorders by addressing the buildup of toxic substances in the body, restoring normal metabolic function, and preventing complications like neurological damage. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 2.0 million deaths from diabetes. Therefore, the increasing prevalence of metabolic disorders drives the growth of the isovaleric acidemia (IVA) treatment industry. The increasing focus on personalized medicine is expected to propel the growth of the isovaleric acidemia (IVA) treatment market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to an individual’s genetic makeup, lifestyle, and environment. The rising focus on personalized medicine is due to advancements in genomic sequencing, which allow for more precise identification of individual genetic variations linked to disease and treatment response. Personalized medicine supports isovaleric acidemia (IVA) treatment by tailoring therapeutic strategies to each patient’s specific IVD gene variants and metabolic profile, enabling more precise correction of enzyme dysfunction and improved clinical outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant increase from 6 in 2022. Therefore, the increasing focus on personalized medicine drives the growth of the isovaleric acidemia (IVA) treatment market.

Key Players In The Global Isovaleric Acidemia (IVA) Treatment Market

Major companies operating in the isovaleric acidemia (iva) treatment market are Nestlé Health Science S.A., Nutricia Advanced Medical Nutrition, Nutricia Metabolics, Vitaflo International Ltd., Abbott Nutrition, Cambrooke Therapeutics Inc., Solace Nutrition LLC, Recordati Rare Diseases Inc., Targeted Medical Pharma Inc., Mead Johnson Nutrition, Ajinomoto Co. Inc., Danone S.A., Orchard Therapeutics plc, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Abeona Therapeutics Inc., Bluebird Bio Inc., Editas Medicine Inc., CRISPR Therapeutics AG

Global Isovaleric Acidemia (IVA) Treatment Market Trends and Insights

Major companies operating in the isovaleric acidemia (IVA) treatment market are focusing on precision‑medicine approaches informed by advanced structural biology, such as high‑resolution cryo‑EM–guided small‑molecule stabilizers of isovaleryl‑CoA dehydrogenase (IVD) to enhance residual IVD enzyme activity, reduce toxic metabolite accumulation, and provide more durable metabolic correction for patients with IVA. High-resolution cryo-EM–guided small-molecule stabilizers of isovaleryl-CoA dehydrogenase (IVD) are precision-engineered drugs designed using detailed cryo-electron microscopy structures to bind and stabilize the faulty IVD enzyme, helping restore its normal metabolic function in isovaleric acidemia. For instance, in June 2025, a research group published the cryo‑EM structure of human IVD, revealing that IVD assembles as a tetramer with a distinctive U‑shaped substrate‑binding channel, and identifying key residues (like E411, T200, and R312) that coordinate FAD and substrate interaction. These insights clarified how disease‑causing mutations disrupt FAD binding, mapped novel binding pockets potentially targetable by stabilizing molecules, and laid the groundwork for rational design of small‑molecule “molecular chaperones” that could rescue mutant IVD function, a promising next‑generation therapeutic strategy in the IVA treatment market.

Regional Insights

North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Isovaleric Acidemia (IVA) Treatment Market?

The isovaleric acidemia (IVA) treatment market consists of revenues earned by entities by providing services such as newborn screening programs, monitoring, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The isovaleric acidemia (IVA) treatment market includes sales of anticatabolic agents, L-carnitine supplements, and amino acid supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Isovaleric Acidemia (IVA) Treatment Market Report 2026?

The isovaleric acidemia (iva) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the isovaleric acidemia (iva) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.